Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection Journal Article


Authors: Park, W.; Chen, J.; Chou, J. F.; Varghese, A. M.; Yu, K. H.; Wong, W.; Capanu, M.; Balachandran, V.; McIntyre, C. A.; El Dika, I.; Khalil, D. N.; Harding, J. J.; Ghalehsari, N.; McKinnell, Z.; Chalasani, S. B.; Makarov, V.; Selenica, P.; Pei, X.; Lecomte, N.; Kelsen, D. P.; Abou-Alfa, G. K.; Robson, M. E.; Zhang, L.; Berger, M. F.; Schultz, N.; Chan, T. A.; Powell, S. N.; Reis-Filho, J. S.; Iacobuzio-Donahue, C. A.; Riaz, N.; O'Reilly, E. M.
Article Title: Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection
Abstract: PURPOSE: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response-targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in maximizing therapeutic outcome. EXPERIMENTAL DESIGN: We evaluated progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage PDAC, who had both germline- and somatic-targeted gene sequencing. Homologous recombination gene mutations (HRm) were evaluated: BRCA1, BRCA2, PALB2, ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, and RTEL1 HRm status was grouped as: (i) germline versus somatic; (ii) core (BRCAs and PALB2) versus non-core (other HRm); and (iii) monoallelic versus biallelic. Genomic instability was compared using large-scale state transition, signature 3, and tumor mutation burden. RESULTS: Among 262 patients, 50 (19%) had HRD (15% germline and 4% somatic). Both groups were analyzed together due to lack of difference in their genomic instability and outcome. Median [95% confidence interval (CI)] follow-up was 21.9 (1.4-57.0) months. Median OS and PFS were 15.5 (14.6-19) and 7 (6.1-8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI: 0.29-0.67); P < 0.01], but not with 1L-non-platinum. Multivariate analysis showed HRD patients had improved OS regardless of their first-line treatment, but most had platinum exposure during their course. Biallelic HRm (11%) and core HRm (12%) had higher genomic instability, which translated to improved PFS on first-line platinum (1L-platinum) versus 1L-non-platinum. CONCLUSIONS: Pathogenic HRm identifies HRD in patients with PDAC with the best outcome when treated with 1L-platinum. Biallelic HRm and core HRm further enriched benefit from 1L-platinum from HRD. ©2020 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 26
Issue: 13
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2020-07-01
Start Page: 3239
End Page: 3247
Language: English
DOI: 10.1158/1078-0432.Ccr-20-0418
PUBMED: 32444418
PROVIDER: scopus
PMCID: PMC7380542
DOI/URL:
Notes: Article -- Export Date: 3 August 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joanne Fu-Lou Chou
    331 Chou
  2. Timothy Chan
    317 Chan
  3. Simon Nicholas Powell
    331 Powell
  4. Mark E Robson
    676 Robson
  5. Nadeem Riaz
    417 Riaz
  6. James Joseph Harding
    250 Harding
  7. Anna Mary Varghese
    145 Varghese
  8. Ghassan Abou-Alfa
    569 Abou-Alfa
  9. Liying Zhang
    129 Zhang
  10. Marinela Capanu
    385 Capanu
  11. Kenneth Ho-Ming Yu
    163 Yu
  12. Nicolas Lecomte
    20 Lecomte
  13. Eileen O'Reilly
    780 O'Reilly
  14. Michael Forman Berger
    765 Berger
  15. David P Kelsen
    537 Kelsen
  16. Nikolaus D Schultz
    487 Schultz
  17. Xin Pei
    134 Pei
  18. Danny Nejad Khalil
    64 Khalil
  19. Vladimir Makarov
    57 Makarov
  20. Imane El Dika
    66 El Dika
  21. Pier Selenica
    190 Selenica
  22. Wungki Park
    98 Park
  23. Winston Wong
    29 Wong
  24. Jiapeng Chen
    5 Chen